In the last days, there have been notable developments in COVID‑19 vaccine formulations, WHO prequalification, and – as reported before – politically driven schedule changes in the US. Very recent product...
Novavax announced a significant regulatory milestone: the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Nuvaxovid™, its recombinant protein-based, non-mRNA COVID-19...